Active	Status	Sponsor type	Region	Phase	Filter
11 Active 3 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Landgren, Carl O
NCT02960555: Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)	Active, not recruiting	2	61	US	Isatuximab, Hu 38SB19, Isatuximab-irfc, SAR 650984, SAR650984, Sarclisa, Laboratory Biomarker Analysis	M.D. Anderson Cancer Center, National Cancer Institute (NCI)	Smoldering Plasma Cell Myeloma	04/25	04/30
NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma	Recruiting	2	306	Europe, US	Bortezomib, Dexamethasone, Lenalidomide, Revlimid, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)	University of Miami, Amgen, Janssen Pharmaceuticals	Multiple Myeloma	02/27	02/27
REVIVE, NCT06100237: Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma ( Study)	Recruiting	2	50	US	Teclistamab, Talquetamab, Daratumumab SC	Carl Ola Landgren, MD, PhD, Janssen Scientific Affairs, LLC	Multiple Myeloma	12/28	12/29
Iber-KDd, NCT05896228: Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone () in Patients With Relapsed/Refractory Multiple Myeloma	Recruiting	2	30	US	Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast	Carl Ola Landgren, MD, PhD, Bristol-Myers Squibb	Refractory Multiple Myeloma, Relapsed Multiple Myeloma	03/29	03/31
NCT05027594: Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma	Terminated	1	5	US	NMS-03597812, NMS-03597812 + dexamethasone	Nerviano Medical Sciences	Multiple Myeloma	08/23	01/24
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma	Recruiting	1	125	Europe, Canada, US	Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide	K36 Therapeutics, Inc.	Multiple Myeloma, Myeloma, Myeloma Multiple	12/25	06/26
TRANSFORMM, NCT05361694: Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions	Recruiting	N/A	1000	US		University of Miami	Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance	07/27	07/27
Armogan, Michelle D
NCT04814615: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma	Recruiting	2	60	US	89Zr-daratumumab PET/CT, CD38-targeted imaging	Hoag Memorial Hospital Presbyterian	Multiple Myeloma	01/26	03/26
REVIVE, NCT06100237: Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma ( Study)	Recruiting	2	50	US	Teclistamab, Talquetamab, Daratumumab SC	Carl Ola Landgren, MD, PhD, Janssen Scientific Affairs, LLC	Multiple Myeloma	12/28	12/29
Iber-KDd, NCT05896228: Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone () in Patients With Relapsed/Refractory Multiple Myeloma	Recruiting	2	30	US	Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast	Carl Ola Landgren, MD, PhD, Bristol-Myers Squibb	Refractory Multiple Myeloma, Relapsed Multiple Myeloma	03/29	03/31
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma	Recruiting	1	125	Europe, Canada, US	Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide	K36 Therapeutics, Inc.	Multiple Myeloma, Myeloma, Myeloma Multiple	12/25	06/26